RIPK1 and myelodysplastic syndrome: The expression of RIPK1 is generally maintained at a normal level in a variety of cancers, but its expression is upregulated in glioblastoma, lung cancer, and MDS, which has a negative impact on cancer prognosis.125, 127, 128, 129